[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fábio Fernandes\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100657282","phase-2-effect-of-trimetazidine-on-coronary-flow-in-transthyretin-cardiac-amyloidosis-100657282",false,"NCT07836699","Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis","Evaluation of the Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis","TACT-TTR","Inclusion Criteria:\n\n* Diagnosis of transthyretin cardiac amyloidosis confirmed by all protocol-specified diagnostic criteria or by Congo red-positive tissue biopsy with cardiac involvement. The diagnostic criteria listed in the current protocol include:\n* Interventricular septal thickness \\>12 mm on echocardiography or cardiac magnetic resonance imaging, in the absence of other causes of hypertrophy (e.g., hypertension or aortic stenosis)\n* History of signs or symptoms of heart failure consistent with cardiac amyloidosis\n* Cardiac scintigraphy with technetium-99m pyrophosphate showing grade II or III uptake according to the Perugini scale\n* Age \\>18 years\n* New York Heart Association (NYHA) functional class II, III, or IV\n\nExclusion Criteria:\n\n* Previous adverse reaction, intolerance, or other contraindication to trimetazidine\n* Serum kappa\u002Flambda ratio outside the normal range\n* Use of calcium channel blockers, beta-blockers, or nitrates\n* Obstructive coronary artery disease, defined as \\>50% stenosis in any major epicardial coronary artery, demonstrated by coronary computed tomography angiography\n* Active infection, inflammatory disease, or other systemic condition that may affect myocardial perfusion\n* Contraindication to dipyridamole or PET\u002FCT imaging\n* Estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m², calculated using the CKD-EPI equation\n* Pregnancy or postpartum period\n* Presence of diseases other than cardiac amyloidosis that may impair functional capacity or limit ambulation during the 6-minute walk test\n* Other medical conditions or comorbidities that, in the investigator's opinion, may interfere with the course of the study or interpretation of the data\n* Refusal to provide written informed consent","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if trimetazidine can improve blood flow in the heart in adults with transthyretin cardiac amyloidosis (ATTR-CM). ATTR-CM is a condition in which an abnormal protein builds up in the heart and can make it harder for the heart to work normally.\n\nThe main question this study aims to answer is:\n\nDoes trimetazidine improve the heart's ability to increase its blood flow when more blood is needed?\n\nThe study will also look at whether treatment is linked to changes in walking ability, heart-related blood tests, heart function, and quality of life.\n\nParticipants will:\n\nTake trimetazidine for about 6 months. Have heart blood flow measured with a positron emission tomography\u002Fcomputed tomography (PET\u002FCT) scan before and after treatment.\n\nHave heart ultrasound examinations and blood tests. Complete a 6-minute walk test and a questionnaire about their symptoms and quality of life.",[27],"Transthyretin Cardiac Amyloidosis",[27,29,30,31,32,33,34,35],"ATTR-CM","Trimetazidine","Coronary Flow Reserve","Coronary Microvascular Dysfunction","Myocardial Blood Flow","Myocardial Perfusion","Nitrogen-13 Ammonia PET\u002FCT","NOT_YET_RECRUITING","2026-09-17",{"date":39,"type":40},"2026-09-23","ACTUAL",{"date":42,"type":21},"2026-09-01",{"date":44,"type":21},"2027-09-01",{"name":46,"class":47},"Fábio Fernandes","OTHER",""]